Stocks · Theme
Managed care & health services stocks · 27 research notes
27 Managed care & health services stocks moving on the same story, each with a dated research note: thesis, kill line and next catalyst.
Active themeStage: maturing, as of 15 November 2026.
All 27 have a dated research note with a published kill line: the note's own test, stated in advance, of what would prove it wrong: a price level, a business fact, or both.
All stocksAGLagilon healthMedium agilon health roughly doubled its 2026 adjusted EBITDA guidance to $145–$155 million after a second profitable quarter, giving the shares a modest edge over the S&P 500; the 17 November 2026 investor event and the Q4 report show whether…BTSGBrightSpring Health ServicesMedium BrightSpring Health Services is growing profit faster than revenue, with third-quarter 2026 adjusted EBITDA up 42% on specialty pharmacy margins and acquired home-health branches. Its first 2027 guidance, expected around late February…CVSCVS HealthMedium CVS Health is modestly more likely to beat the S&P 500 over three months: Aetna's costs improved and 2026 guidance rose, and the February 2027 report tests the 2027 outlook of at least $8.65 per share.EVHEvolent HealthMedium Evolent Health's margin repair now has evidence: Q3 medical costs fell to 93.0% of revenue and 2026 adjusted EBITDA guidance rose to $130–135 million. The late-February Q4 report, with its 2027 range, decides whether the $150 million-plus…HNGEHinge HealthMedium Hinge Health's shares can lead the S&P 500 on 52% revenue growth and a raised $879–881 million 2026 guide; the February 2027 report must show fourth-quarter revenue of at least $249 million to keep the case.HUMHumanaMedium Humana's third-quarter cost beat and higher $9.50 adjusted EPS floor, reported 6 November 2026, make its shares modestly more likely than not to beat the S&P 500 as the Star Ratings recovery lifts 2028 margins. The 10 December investor…LHLabcorp HoldingsMedium Labcorp's 11.5% Central Labs growth and raised 2026 guidance make its shares modestly more likely to beat the S&P 500 over three months. Final 2027 Medicare lab rates, due from CMS in late November 2026, test the case, and the February…MCKMcKessonMedium McKesson's earnings keep beating its own guidance, which rose to $45.60–$46.40 of fiscal 2027 adjusted EPS on 4 November 2026; the fiscal third-quarter report, expected in early February 2027, shows whether profit growth holds as oncology…TDOCTeladoc HealthMedium Teladoc Health's Q3 2026 beat and fast-growing BetterHelp insurance revenue give the shares a modest edge over the S&P 500. The refinancing of $1.0 billion of notes due June 2027 and the Q4 report settle whether the turnaround holds.UNHUnitedHealth GroupMedium UnitedHealth Group's earnings recovery, with 2026 adjusted EPS guided to at least $20.50 and a buyback widened by 50 million shares, gives the shares a modest edge over the S&P 500; the 7 December 2026 Medicare enrollment close and the…AMNAMN Healthcare ServicesLow AMN Healthcare Services is more likely to lag the S&P 500 because its fourth-quarter outlook cuts strike revenue to $5 million from $59 million and resets margins lower; the report expected around February 2027 shows whether nurse staffing…HIMSHims & Hers HealthLow Hims & Hers Health shares are more likely to lag the S&P 500 after a 9 November 2026 report showing 57% gross margin and a flat fourth-quarter revenue guide. November weight-loss billing data and early Lilly drug sales show whether growth…ACHCAcadia HealthcareMedium Acadia Healthcare is modestly more likely than not to beat the S&P 500 over three months: on 4 November 2026 it raised fiscal 2026 adjusted EBITDA guidance to $615–625 million. The fourth-quarter results, expected in late February 2027,…ARDTArdent HealthMedium Ardent Health's cost-led hospital turnaround is running ahead of plan, with 2026 adjusted EBITDA guidance raised to $500–$535 million and Guggenheim and Stephens targets at $21; the 2027 outlook due with year-end results settles whether…AVAHAveanna Healthcare HoldingsMedium Aveanna Healthcare's shares are modestly more likely than not to beat the S&P 500 over three months: on 12 November 2026 it beat estimates and raised its 2026 outlook, yet the shares fell to $12.24. The fourth-quarter report in early 2027…CLOVClover Health InvestmentsMedium Clover Health's profit is rising with Medicare Advantage membership, and the 4 November 2026 quarter lifted full-year guidance; the CMS appeal of the court-ordered Star Rating remains the event that can reverse the gains.CNCCenteneMedium Centene is more likely to beat the S&P 500 over three months: its raised 2026 adjusted EPS guidance of more than $5.20 shows medical costs improving. The fourth-quarter report, expected in February 2027, settles whether it holds.DVADaVitaMedium DaVita is modestly more likely than not to beat the S&P 500 over three months: the third-quarter beat lifted 2026 adjusted EPS guidance to $14.30–$15.20, though shares fell to $174.07 on 12 November 2026. The February 2027 fourth-quarter…INNVInnovAge HoldingMedium InnovAge's earnings recovery gives the shares a modest edge over the S&P 500 over three months, but private-equity selling at $9.25 caps the move; the second-quarter fiscal 2027 report, expected around February 2027, tests whether the…OSCROscar HealthMedium Oscar Health is modestly likely to beat the S&P 500: it raised 2026 earnings-from-operations guidance to $850–950 million on 5 November 2026 and is expanding for 2027. Open-enrollment results and the fourth-quarter report settle it.PGNYProgynyMedium Progyny's record 1.3 million new covered lives and raised 2026 outlook keep the shares modestly more likely than not to beat the S&P 500 over three months, though they trade above the $35.33 average analyst target; the first 2027 guidance,…THCTenet Healthcare Corporation NewMedium Tenet Healthcare is more likely to lead the S&P 500 over three months: hospital margin hit 19.2% and 2026 guidance rose again. The fourth-quarter report, expected around February 2027, shows whether margin holds without a $147 million…ALHCAlignment HealthcareLow Alignment Healthcare's 29 October 2026 cut to full-year profit guidance makes the shares more likely to lag the S&P 500 over three months; the fourth-quarter report, expected around February 2027, shows whether medical costs are turning.ASTHAstrana HealthLow Astrana Health is more likely to lag the S&P 500 over three months: fourth-quarter adjusted EBITDA is guided to $48.5–61.5 million against $77.2 million in the third quarter, and Medicaid costs run above plan. Medicare Advantage contracts…LFSTLifeStance Health GroupLow LifeStance Health shares are more likely to lag the S&P 500 over the next three months because holders keep selling into the profit upturn, including 45 million shares at $13.12 on 9 November 2026. The fourth-quarter report, estimated for…OMDAOmada HealthLow Omada Health beat and raised on 5 November 2026, yet the shares fell 20.37% on 6 November 2026 and closed at $15.09 on 9 November 2026, because revenue growth slowed to 34% and 2027 is unquantified. The fourth-quarter report and 2027…STLNStarling OncologyLow Starling Oncology's shares are more likely to lag the S&P 500 after it cut 2026 capitated revenue to about $110 million from $150 million and a 10% owner sold 2.85 million shares; the fourth-quarter report, expected around March 2027,…